Drug Profile
Research programme: mGlu3 receptor allosteric modulators - Addex Therapeutics/Pierre Fabre Pharmaceuticals
Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Addex Therapeutics
- Developer Addex Therapeutics; Pierre Fabre
- Class
- Mechanism of Action Metabotropic glutamate receptor 3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in CNS-disorders in France
- 28 Mar 2024 No recent reports of development identified for research development in CNS-disorders in Switzerland
- 07 Mar 2022 Early research development is ongoing in Switzerland and France